Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
49 studies found for:    Acorda
Show Display Options
Rank Status Study
1 Completed Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.
Condition: Multiple Sclerosis
Intervention: Drug: BIIB041 (Fampridine-SR)
2 Completed
Has Results
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
Condition: Multiple Sclerosis
Intervention: Drug: Fampridine-SR
3 Completed
Has Results
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Fampridine-SR b.i.d. (Twice Daily)
4 Completed
Has Results
Study of Oral Fampridine-SR in Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Fampridine-SR;   Drug: Placebo
5 Completed An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: rHIgM22
6 Completed A Study to Determine the Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)
Condition: Refractory Epilepsy
Interventions: Drug: diazepam nasal spray;   Drug: diazepam rectal gel
7 Active, not recruiting An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the DALF-PS-1016 Study
Condition: Post-ischemic Stroke
Interventions: Drug: dalfampridine-ER 7.5 mg;   Drug: dalfampridine-ER 10 mg
8 Completed An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults With Cluster Seizures
Condition: Epilepsy
Intervention: Drug: diazepam nasal spray
9 Completed A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke
Condition: Post-Ischemic Stroke
Interventions: Drug: Placebo;   Drug: dalfampridine-ER 7.5mg;   Drug: dalfampridine-ER 10mg
10 Completed
Has Results
A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
Condition: Ischemic Stroke
Interventions: Drug: placebo/dalfampridine-ER;   Drug: dalfampridine-ER/placebo
11 Recruiting Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
Condition: Idiopathic Parkinson's Disease
Intervention: Drug: CVT-301
12 Active, not recruiting Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
Condition: Idiopathic Parkinson's Disease
Intervention: Drug: CVT-301
13 Active, not recruiting Randomized Safety Study of CVT-301 Compared to an Observational Control Group
Condition: Idiopathic Parkinson's Disease
Interventions: Drug: CVT-301;   Other: Observational cohort
14 Recruiting A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
Condition: Migraine
Interventions: Drug: CVT-427 (zolmitriptan inhalation powder);   Other: Placebo
15 Completed A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets
Condition: Parkinson Disease
Interventions: Drug: CVT-301 (Dose Level 1);   Drug: CVT-301 (Dose Level 2);   Drug: Sinemet®
16 Recruiting A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)
Condition: Parkinson's Disease
Interventions: Drug: CVT-301, LIP;   Other: Placebo
17 Completed A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers
Condition: Healthy
Intervention: Drug: diazepam nasal spray
18 Completed A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults
Condition: Smoking
Interventions: Drug: CVT-301;   Drug: Carbidopa
19 Completed A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma
Condition: Asthma
Interventions: Drug: CVT-301 (levodopa inhalation powder);   Drug: Carbidopa;   Other: Placebo
20 Completed Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
Condition: Migraine
Interventions: Drug: zolmitriptan;   Drug: CVT-427 (zolmitriptan inhalation powder),

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.